Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC).
Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma
Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences. Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma
Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia
BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer. Plinabulin is a first-in-class differentiated immune and stem cell modulator.
Kesimpta® (ofatumumab), The First Self Administrated B-cell Therapy Developed
Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS). Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen.
GSK Introduces a New Anti-BCMA (B-cell maturation antigen) Therapy, BLENREP
GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody
AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy
Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor. AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment
Rozlytrek® (entrectinib), The First Tumour-Agnostic Therapy Discovered
Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies.
AstraZeneca Introduces A Breakthrough Therapy-Tagrisso
AstraZeneca introduced Tagrisso (osimertinib), a breakthrough therapy for the adjuvant treatment of patients with early-stage (IB, II and IIIA) Epidermal Growth Factor Receptor-mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC).
Merck Discovers Breakthrough Therapy HIF-2α Inhibitor MK-6482
Hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel breakthrough therapy discovered by Merck for the treatment of patients with von Hippel-Lindau (VHL) disease-associated Renal Cell Carcinoma (RCC).
Pevonedistat Novel Therapy Developed for the Treatment of Patients with HR-MDS
Takeda Pharmaceutical has developed Pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor,a novel treatment for Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients.
